Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Morton

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
American Journal of Physiology. Cell Physiology|May 16, 2019
Erythrocyte ion content and dehydration modulate maximal Gardos channel activity in KCNN4 V282M/+ hereditary xerocytosis red cellsAlicia Rivera, David H Vandorpe, Boris E Shmukler, et al.
Blood Cells, Molecules & Diseases|December 14, 2019
Genetic disruption of KCC cotransporters in a mouse model of thalassemia intermediaBoris E Shmukler, Alicia Rivera, Parul Bhargava, et al.
Blood|August 5, 2004
Duration of immunosuppressive treatment for chronic graft-versus-host diseaseBetty L Stewart, Barry Storer, Jan Storek, et al.
Blood|January 29, 2021
A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxisGlen A Kennedy, Siok-Keen Tey, Luke Buizen, et al.
Blood|September 5, 2008
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapyTimothy P Hughes, Susan Branford, Deborah L White, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2018
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN StudyAjay K Gopal, Stephen J Schuster, Nathan H Fowler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2019
Phase I Trial of Inducible Caspase 9 T Cells in Adult Stem Cell Transplant Demonstrates Massive Clonotypic Proliferative Potential and Long-term Persistence of Transgenic T CellsPing Zhang, Jyothy Raju, Md Ashik Ullah, et al.
The Lancet. Oncology|December 3, 2014
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trialGlen A Kennedy, Antiopi Varelias, Slavica Vuckovic, et al.
Blood Cancer Journal|November 5, 2020
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUXJonathan L Kaufman, Meletios A Dimopoulos, Darrell White, et al.
Haematologica|September 22, 2018
Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXMeletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
American Journal of Physiology. Cell Physiology|May 16, 2019
Erythrocyte ion content and dehydration modulate maximal Gardos channel activity in KCNN4 V282M/+ hereditary xerocytosis red cellsAlicia Rivera, David H Vandorpe, Boris E Shmukler, et al.
Blood Cells, Molecules & Diseases|December 14, 2019
Genetic disruption of KCC cotransporters in a mouse model of thalassemia intermediaBoris E Shmukler, Alicia Rivera, Parul Bhargava, et al.
Blood|August 5, 2004
Duration of immunosuppressive treatment for chronic graft-versus-host diseaseBetty L Stewart, Barry Storer, Jan Storek, et al.
Blood|January 29, 2021
A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxisGlen A Kennedy, Siok-Keen Tey, Luke Buizen, et al.
Blood|September 5, 2008
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapyTimothy P Hughes, Susan Branford, Deborah L White, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2018
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN StudyAjay K Gopal, Stephen J Schuster, Nathan H Fowler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2019
Phase I Trial of Inducible Caspase 9 T Cells in Adult Stem Cell Transplant Demonstrates Massive Clonotypic Proliferative Potential and Long-term Persistence of Transgenic T CellsPing Zhang, Jyothy Raju, Md Ashik Ullah, et al.
The Lancet. Oncology|December 3, 2014
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trialGlen A Kennedy, Antiopi Varelias, Slavica Vuckovic, et al.
Blood Cancer Journal|November 5, 2020
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUXJonathan L Kaufman, Meletios A Dimopoulos, Darrell White, et al.
Haematologica|September 22, 2018
Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXMeletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, et al.
Pageof 6